VGX-1027 is the company’s lead drug candidate for the treatment of inflammatory diseases rheumatoid arthritis (RA) and type 1 diabetes (T1D) and is currently in Phase I trials. VGX-1027 is an immune modulator that inhibits production of several pro-inflammatory cytokines that are responsible for the damaging effects of inflammatory diseases. Pre-clinical studies have shown that VGX-1027 is effective in inhibiting these cytokines by blocking NF-kB and transiently inhibiting the p38 signaling pathway, while JNK and AP-1 pathways are unaffected.

VGX Pharmaceuticals is developing VGX-1027 as an oral therapeutic for RA. We are co-developing VGX-1027 for T1D with our affiliate, VGX International.

VGX-1027 - An orally active small molecule drug for treating RA/T1D